Full Press Release Details
Pharmaceuticals Provides Second Quarter 2023 Corporate Update
Md., August 15, 2023 - Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical
company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection
with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.
are making significant progress in the advancement of Ropidoxuridine, our lead clinical sensitizer drug candidate, for treatment in brain
cancer patients undergoing radiation therapy. During the last few months, we successfully completed the initial manufacturing campaign
for the API to be used in the upcoming Phase II clinical trial and received approval from the FDA for a Type B pre-IND meeting to receive
guidance on the trial design," commented Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D. "We expect to
receive comments from the FDA by mid-September which would put us in position to initiate the clinical trial in the fourth quarter of
this year - a significant inflection point in the development of Ropidoxuridine."
move into our new laboratory will accommodate not only our Ropidoxuridine research efforts, but also enhance our ability to establish
a CLIA laboratory to advance our diagnostic intellectual property that has been developed with funding from NIH small business innovative
(SBIR) research contracts over the past several years, particularly for our predictive biomarker capabilities for prostate cancer patients.
We are eligible for NIH SBIR bridge' support to assist in funding the advancements of these efforts. Our recently published
work in premier cancer journals provides insight into the immune response taking place in patients after radiation therapy for cancer
and informs therapeutic strategies for sequencing radiation and immune therapy modalities for cancer treatment," Dr. Dritschilo
Shuttle Pharmaceuticals
in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty
pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve
the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects
of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim
to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination
with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not
historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements
concerning the development of our company. The words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "will," "would" and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual
results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including
factors discussed in the "Risk Factors" section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December
31, 2022, filed with the SEC on March 15, 2023, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 and June
30, 2023, filed with the SEC on May 25, 2023 and August 14, 2023, respectively, as well other SEC filings. Any forward-looking statements
contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals
specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events
Dritschilo, M.D., CEO